Journal articles


[46] Seon Ah Lee1, Juyeon Lee1, Jongyoon Shinn1, Seon Ju Lee, Yejin Kim, Joohyeon Kim, Jonghee Choi, Byungchae Jung, Taeho Kim, HyeonTaek Nam, Ah Hyun Choi, Hyungjun Kim*, and Yonghyun Lee*. “Strategies for oral siRNA delivery to treat inflammatory bowel disease” Pharmaceutics, (IF 6.525). 1These authors contributed equally to this work.

[45] Yonghyun Lee*, Jongyoon Shinn, Cheng Xu, Nouri Neamati, and James Moon*. “Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy” Nature Communication, (IF 17.694) Under revision *Co-corresponding authors

[44] Jongyoon Shinn1, Nuri Kwon1, Seon Ah Lee, and Yonghyun Lee*. “Smart pH-Responsive Nanomedicines for Disease Therapy” Journal of Pharmaceutical Investigation, 2022 May 09: (IF 4.946) [Link] **Featured by Ewha COP news [Link].


[43] Yonghyun Lee*, Nobuhiko Kamda, and James Moon*. “Oral Nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome” Advanced Drug Delivery Reviews, 2021 Dec 01: 179: 114021 (IF 17.873) [Link] *Co-corresponding authors

[42] Jongyoon Shinn1, Sunyoung Lee1, Hyon Kyong Lee1, Jaeeun Ahn1, Seon Ah Lee, Seonju Lee, and Yonghyun Lee*. “Recent Progress in Development and Applications of Second Near-infrared (NIR-II) NanoprobesArchives of Pharmacal Research, 2021 Feb 04: 44: 165-181. (IF 6.010) 1These authors contributed equally to this work. [Link] **Featured by Ewha COP news [Link], KPAnews [Link]


[41] Yonghyun Lee*, Jungyun Kim, Wooseong Kim, In-Soo Yoon, and Yunjin Jung*. “Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetics and Therapeutic Properties of Celecoxib” Pharmaceutics, 2020 Oct 30: 12(11), 1043, 1-13 (IF 6.525) *Co-corresponding authors. [Link]

[40] Cheng Xu, Hao Hong, Yonghyun Lee, Kyung Soo Park, Mingjiao Sun, Tianuri Wang, Marisa E Aikins, Yao Xu, and James J Moon. “Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets.” ACS Nano, 2020 Sep 9. (IF 15.881) [Link]

[39] Dong Yun Lee, Sukmo Kang, Yonghyun Lee, Jin Yong Kim, Dohyun Yoo, Wonsik Jung, Soyoung Lee, Yong Yeon Jeong, Kwangyeol Lee, and Sangyong Jon. "PEGylated bilirubin-coted Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS detection in Whole Blood." Theranostics. 2020 Jan 12:10 (5): 1997-2007. (IF 11.546) [Link]

[38] Yonghyun Lee, Kohei Sugihara, Merritt G. Gilliland III, Sangyong Jon, Nobuhiko Kamada, and James J. Moon. “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome, and immune responses in colitis.” Nature Materials. 2020 Jan 1: 19 (1): 118-126. (IF 43.841) [Link] **Featured by New England Journal of Medicine (NEJM) [Link], Nature Materials [Link]

2016 - 2019

[37] Byeongjun Yu, Dobeen Hwang, Hyungsu Jeon, Hyungjun Kim, Yonghyun Lee, Hyeongseop Keum, Jinjoo Kim, Dong Yun Lee, Yujin Kim, Junho Chung, Sangyong Jon. "A hybrid platform based on a bispecific peptide-antibody complex for targeted cancer therapy" Angewantde chemie. 2019 Feb 11:58(7):2005-2019 (IF 12.257)

[36] Hyungjun Kim, Dobeen Hwang, Minsuk Choi, Soyoung Lee, Sukmo Kang, Yonghyun Lee, Sunghyun Kim, Junho Chung, and Sangyong Jon. “Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy” Molecular Pharmaceutics. 2018 Dec 6:16(1):165-172 (IF 4.396)

[35] Joon Nam*, Yonghyun Lee*, Yejin Yang, Seongkeun Jung, Wooseong Kim, Jin-Wook Yoo, Jeon-Ok Moon, Changyong Lee, Hae Young Chung, Minsoo Kim, Sangyong Jon, and Yunjin Jung. “Is it worth expending energy to convert biliverdin into bilirubin?” Free Radical Biology and Medicine. 2018 Aug 20;124:232-240. (IF 5.657). *These authors contributed equally to this work.

[34] Soyoung Lee, Yonghyun Lee, Hyungjun Kim, Dongyun Lee and Sangyong Jon. “Bilirubin nanoparticle-assisted delivery of a small molecule-drug conjugate for targeted cancer therapy” Biomacromolecules. 2018 Jun 11;19(6):2270-2277. (IF 5.667)

[33] Yonghyun Lee, Soyoung Lee, and Sangyong Jon. “Biotinylated bilirubin nanoparticles as a tumor microenvironment-responsive drug delivery system for targeted cancer therapy” Advanced Science. 2018 Apr 24; 5(6):1800017. (IF 15.804).

[32] Dong Yun Lee, Jin Yong Kim, Yonghyun Lee, Soyoung Lee, Wenjun Miao, Hyeon Sik Kim, Jung-Joon Min, and Sangyong Jon. “Black pigment gallstone-inspired platinum-chelated bilirubin nanoparticles for combined photoacoustic imaging and photothermal therapy of cancers” Angewantde chemie. 2017 Oct 23:56(44):13684-13688. (IF 12.257)

[31] Dong-eon Kim*, Yonghyun Lee*, Mingyo Kim, Soyoung Lee, Sangyong Jon, and Seung-Hyo Lee. “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma” Biomaterials. 2017 Sep;140:37-44. (IF 10.273). *These authors contributed equally to this work.

[30] Sookjin Kang*, Wooseong Kim*, Seongkeun Jeong*, Yonghyun Lee*, Joon Nam, Sunyoung Lee and Yunjin Jung. “Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid” Free Radical Biology and Medicine. 2017 Jul;108:715-724. (IF 6.202). *These authors contributed equally to this work.

[29] Min Jun Kim, Yonghyun Lee, Sangyong Jon and Dong Yun Lee. “PEGylated bilirubin nanoparticles as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation” Biomaterials. 2017 Jul;133:242-252. (IF 10.273).

[28] Jin Yong Kim, Dong Yun Lee, Sukmo Kang, Wenjun Miao, Hyungjun Kim, Yonghyun Lee and Sangyong Jon. “Bilirubin nanoparticles preconditioning protects against hepatic ischemia-reperfusion injury.” Biomaterials. 2017 Jul;133:1-10. (IF 10.273).

[27] Yonghyun Lee, Sunghyun Kim, Daejin Kim, and Sangyong Jon “A histone H1-binding-aptide–based apoptosis imaging probe for monitoring tumor responses to cancer therapy” MedChemComm. 2017 Jan 5;8(2):390-393 (IF 2.394).

[26] Hyungjun Kim, Yonghyun Lee, Sukmo Kang, Minsuk Choi, Jinju Lee, Vipul Gujrati, and Sangyong Jon. “self-assembled nanoparticles comprised of aptide-SN38 conjugates for targeted cancer therapy.” Nanotechnology. 2016 Dec 2;27(48):48LT01. (IF 3.399).

[25] Wenjun Miao, Hyungjun Kim, Vipul Gujrati, Jinyong Kim, Hyungsu Jeon, Yonghyun Lee, Minsuk Choi, Jinjoo Kim, Soyoung Lee, Dongyun Lee, Sukmo Kang, and Sangyong Jon. “Photo-decomposable Organic Nanoparticles for Combined Tumor Optical Imaging and Multiple Phototherapies” Theranostics. 2016 Oct 1;6(13):2367-2379. (IF 8.063).

[24] Yonghyun Lee, Soyoung Lee, Dong Yun Lee, Byeongjun Yu, Wenjun Miao, and Sangyong Jon “Multi-stimuli-responsive bilirubin nanoparticles for anticancer therapy.” Angewandte chemie. 2016 Aug 26;55(36):10676-10680. (IF 12.257). Selected by the editors of Angewandte Chemie as a “Hot paper” (top 10% of all Angewandte publications).

[23] Yonghyun Lee, Hyungjun Kim, Sukmo Kang, Jinju Lee, Jinho Park, and Sangyong Jon. “Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy.” Angewantde chemie. 2016 Jun 20;55(26):7460-7463. (IF 12.257)

[22] Jinju Lee, Phei Er Saw, Vipul Gujrati, Yonghyun Lee, Hyungjun Kim, Sukmo Kang, Minsuk Choi, Jinjoo Kim, Jae-Il Kim, and Sangyong Jon. “Mono-arginine cholesterol-based small lipid nanoparticles as a systemic siRNA delivery platform for effective cancer therapy.” Theranostics. 2016 Jan 1;6(2):192-203. (IF 8.063)

2013 - 2015

[21] Sunyoung Lee*, Yonghyun Lee*, Wooseong Kim, Joon Nam, Seongkeum Jeong, Jin-Wook Yoo, Minsoo Kim, Hyung Ryong Moon, and Yunjin Jung. “Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on NF kappaB, an anti-inflammatory target.” Drug Design, Development and Therapy. 2015 Aug 7;9:4227-4237. (IF 3.208) *These authors contributed equally to this work.

[20] Yonghyun Lee, Jungyoon Kim, Wooseong Kim, Joon Nam, Seongkeum Jeong, Sunyoung Lee, Jin-Wook Yoo, Minsoo Kim, and Yunjin Jung. “Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.” Drug Design, Development and Therapy. 2015 Jul 30;9:4105-4113. (IF 3.208)

[19] Wooseong Kim*, Yonghyun Lee*, Seongkeun Jeong, Joon Nam, Sunyoung Lee, and Yunjin Jung. “Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.” Archives of pharmacal research. 2015 Oct;38(10):1830-1838. (IF 2.458) *These authors contributed equally to this work.

[18] Sunghyun Kim, Daejin Kim, Yonghyun Lee, Byung-Heon Lee, and Sangyong Jon. “Conversion of low-affinity to high-affinity peptide by a beta-hairpin scaffold-assisted approach.” ChemBioChem. 2015 Jan 2;16(1):43-46. (IF 2.593)

[17] Hyungjun Kim, Eunhye Lee, In-Hyun Lee, Jinju Lee, Jinjoo Kim, Sunghyun Kim, Yonghyun Lee, Daejin Kim, Minsuk Choi, Yong-Chul Kim, and Sangyong Jon. “Preparation and therapeutic evaluation of paclitaxel-conjugated low-molecular-weight chitosan nanoparticles.” Macromol Res. 2014 Aug;22(8):805-808 (IF 1.758)

[16] Hyungjun Kim, Yonghyun Lee, In-Hyun Lee, Sunghyun Kim, Daejin Kim, Phei Er Saw, Jinju Lee, Minsuk Choi, Yong-Chul Kim, and Sangyong Jon. “Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin.” Journal of controlled release. 2014 Mar 28;178:118-124. (IF 7.901)

[15] Yonghyun Lee, Wooseong Kim, Sungchae Hong, Huijeong Park, Soohwan Yum, Jeong-Hyun Yoon, and Yunjin Jung. “Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.” European journal of pharmacology. 2014 Mar 5;726 (1):49-56 (IF 3.17)

[14] Yonghyun Lee, Seongkeun Jeong, Wooseong Kim, Hyunjeong Kim, Jeong-Hyun Yoon, Seong Hoon Jeong, and Yunjin Jung. “Glycyrrhizin Enhances Therapeutic Activity of a Colon-Specific Methylprednisolone Prodrug Against Experimental Colitis.” Digestive diseases and sciences. 2013 May 1;58(5):1226-1234. (IF 2.937)

[13] Hyunsoo Kim, Tae Gan Son, Hee Ra Park, Yonghyun Lee, Yunjin Jung, Akihito ishigami, and Jaewon Lee. “Senescence marker protein 30 deficiency increases Parkinson`s pathology by impairing astrocyte activation.” Neurobiology of Aging. 2013 Apr 1;34(4):1177-1183. (IF 4.398)

2009 - 2012

[12] Yonghyun Lee, Hyunjeong Kim, Wooseong Kim, Jeong-Hyun Yoon, Seong Hoon Jeong, and Yunjin Jung. “Colon-specific delivery of celecoxibis a potential strategy to improve toxicological and pharmacological properties of the selective COX-2 inhibitor: implication in treatment of familiar adenomatous polyposis.” Journal of drug targeting. 2012 Jul 1;20(6):524-534.( IF 3.227)

[11] Yonghyun Lee, Eun Hee Jung, Hyunjung Kim, Jeong-Hyun Yoon, Dae-Duk Kim, and Yunjin Jung. “Preparation and in vitro evaluation of celecoxib-amino acid conjugates as a colon specific prodrug.” Journal of Pharmaceutical Investigation. 2012 Jun 1

[10] Yonghyun Lee, Jeongyun Kim, Hyunjeong Kim, Sookjin Kang, Jeong-Hyun Yoon, Dae-Duk Kim, Young-Mi Kim, and Yunjin Jung. “N-succinylaspart-1-yl celecoxib is a potential colon specific prodrug of celecoxib with improved therapeutic properties.” Journal of pharmaceutical science. 2012 May 1;101(5):1831-1842. (IF 3.197)

[9] Hyunjeong Kim*, Yonghyun Lee*, Hansun Yoo, Jihye Kim, Hyesik Kong, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Synthesis and evaluation of sulfate conjugated metronidazole as a colon specific prodrug of metronidazole.” Journal of drug targeting. 2012 Apr 1;20(3):255-263. (IF 3.227) *These authors contributed equally to this work.

[8] Hyesik Kong, Yonghyun Lee, Hyunjeong Kim, Dae-Duk Kim, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Susceptibility of glucocorticoids to colonic metabolism and pharmacologic intervention in the metabolism: implication for therapeutic activity of colon-specific glucocorticoid 21-sulfate sodium at the target site.” Journal of pharmacy and pharmacology. 2012 Jan 1;64(1):128-138. (IF 2.39)

[7] Hyesik Kong, Hyunjeong Kim, Heejeong Do, Yonghyun Lee, Sungchae Hong, Jeong-Hyun Yoon, Yunjin Jung, and Young-Mi Kim. “Structural effects of N-aromatic acyl-amino acid conjugates on their deconjugation in the cecal contents of rats: implication in design of a colon-specific prodrug with controlled conversion rate at the target site.” Biopharmaceutics & drug disposition. 2011 Nov 18;32(6):343-354. (IF 1.611)

[6] Yonghyun Lee, In Ho Kim, Jeongyun Kim, Jeong-Hyun Yoon, Young Hee Shin, Yunjin Jung, and Young-Mi Kim. “Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy.” Journal of drug targeting. 2011 Jul 8;19(5):336-343. (IF 3.227)

[5] Ji-Hye Kim, Jung-Yoon Kim, Yonghyun Lee, Young-Mi Kim, and Yunjin Jung. “Structural analysis of 5-aminosalicyl-L-glutamic Acid, a colon-specific prodrug of 5-aminosalicylic acid, for colon-specific deconjugation.” Journal of Pharmaceutical Investigation. 08/2010

[4] Hyesik Kong, Yonghyun Lee, Sungchae Hong, Jeongoh Han, Biom Choi, Yunjin Jung, and Young-Mi Kim. “Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis.” Journal of drug targeting. 2009 Jul 1;17(6):450-458. (IF 3.227)

[3] Hyo-Sik Kong, You-Na Lee, Yonghyun Lee, Young-Mi Kim, and Yunjin Jung. “Preparation and evaluation of microcrystallized cellulose xanthate-metal-oxytetracyclinecomplexes as antibacterial agents with prolonged antibacterial activity.” Journal of Pharmaceutical Investigation.

[2] Inho Kim, Hyesik Kong, Yonghyun Lee, Sungchae Hong, Jungoh Han, Sunhwa Jung, Yunjin Jung, and Young-Mi Kim. “Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.” Pharm Res. 2009 Feb 1;26(2):415-421. (IF 3.896)

[1] Hyesik Kong*, Youngsoo Kim*, Yonghyun Lee*, Boim Choi, Sunhwa Jung, Yunjin Jung, and Young-Mi Kim. “Sulfate-conjugated methylprednisolone: Evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone.” Journal of drug targeting. 2009 Jan 1;17(2):159-167 (IF 3.227) *These authors contributed equally to this work.